sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
caus
agent
sar
protein
sarscov
major
target
neutral
antibodi
nab
infect
patient
develop
neutral
assay
use
recombin
vesicular
stomat
viru
vsv
bear
sarscov
protein
total
serum
sampl
collect
healthcar
worker
hanoi
french
hospit
sar
epidem
evalu
compar
convent
neutral
assay
use
infecti
sarscov
result
neutral
assay
use
pseudotyp
show
good
correl
use
infecti
sarscov
newli
develop
neutral
assay
sensit
low
antibodi
titer
serum
sampl
thu
use
tool
detect
nab
sarscov
sever
acut
respiratori
syndrom
sar
recent
emerg
lifethreaten
respiratori
diseas
creat
intern
concern
novelti
communic
rapid
spread
lead
worldwid
outbreak
develop
earli
rapid
reliabl
diagnost
assay
system
high
prioriti
earli
vigil
prevent
spread
diseas
identif
sarscoronaviru
sarscov
caus
agent
sar
led
develop
genomebas
serolog
assay
diagnosi
viral
infect
hong
et
al
hourfar
et
al
saijo
et
al
detect
viru
neutral
antibodi
nab
import
assess
immun
respons
sarscovinfect
patient
howev
convent
viru
neutral
assay
requir
handl
infecti
replicationcompet
sarscov
rais
number
import
safeti
concern
furthermor
take
least
day
obtain
result
detect
level
viru
replic
requir
pseudotyp
virus
provid
safe
tool
virolog
studi
inabl
produc
infecti
progeni
viru
takada
et
al
quantit
assay
pseudotyp
viru
infect
could
facilit
research
viru
entri
cell
tropism
viru
neutral
entri
sarscov
suscept
cell
mediat
bind
viral
protein
receptor
molecul
angiotensin
iconvert
enzym
ii
li
et
al
recent
report
recombin
vesicular
stomat
viru
vsv
g
gene
replac
green
fluoresc
protein
gfp
gene
could
pseudotyp
protein
sarscov
infect
sarscov
proteinbear
vsv
pseudotyp
mediat
protein
manner
sarscov
protein
major
target
nab
hofmann
et
al
expect
nab
human
serum
sampl
also
neutral
present
studi
novel
nab
assay
use
develop
perform
compar
convent
nab
assay
use
infecti
sarscov
fiftysix
serum
sampl
collect
healthcar
worker
hanoi
french
hospit
ho
chi
min
citi
sar
outbreak
februari
april
use
studi
sera
use
serolog
analys
heatinactiv
min
sarscov
use
present
studi
kindli
suppli
dr
js
malik
peiri
depart
microbiolog
univers
hong
kong
viru
propag
vero
cell
infecti
titer
plaqu
form
uml
determin
vero
cell
gener
perform
describ
previous
briefli
hr
transfect
cell
express
plasmid
encod
cterminaltrunc
version
sarscov
protein
cell
infect
vsvdg
kindli
provid
dr
whitt
gtx
inc
absorpt
hr
inoculum
replac
cultur
medium
cultur
hr
co
incub
cultur
supernat
collect
filter
size
filter
store
use
titer
infecti
unit
iu
pseudotyp
virus
mean
number
gfpposit
cell
determin
endpoint
dilut
use
vero
cell
pseudotyp
vsv
produc
infecti
progeni
viru
pseudotypebas
neutral
requir
higher
amount
pseudotyp
viru
iu
sarscov
plaqu
form
unit
pfu
convent
neutral
assay
iu
optimum
amount
pseudotypebas
neutral
assay
serum
sampl
dilut
twofold
dulbecco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
fb
iu
mixtur
incub
hr
neutral
incub
mixtur
inocul
onto
vero
cell
seed
plate
infect
determin
count
number
gfpposit
cell
accord
method
describ
previous
nab
titer
defin
reciproc
highest
dilut
inhibit
infect
observ
convent
neutral
assay
use
infecti
sarscov
isol
kindli
suppli
dr
js
malik
peiri
perform
describ
saijo
et
al
briefli
heatinactiv
serum
sampl
dilut
twofold
eagl
minimum
essenti
medium
mem
contain
fb
test
sampl
ml
volum
mix
volum
sarscov
infecti
dose
pfu
mixtur
incub
hr
neutral
incub
mixtur
test
neutral
cytopath
effect
cpe
inhibit
assay
use
vero
cell
cutoff
valu
set
serum
dilut
nab
titer
defin
reciproc
highest
dilut
cpe
observ
recent
report
rabbit
antibodi
rais
purifi
inactiv
sarscov
neutral
infect
vero
cell
examin
whether
nab
induc
sarscovinfect
patient
neutral
infect
serum
sampl
collect
healthcar
worker
hanoi
french
hospit
sar
epidem
use
although
clinic
inform
subject
avail
sera
shown
seroconvert
convent
sarscov
neutral
assay
sarscovrecombin
np
rnp
base
elisa
sarscov
antibodyneg
control
human
sera
show
nonspecif
antipseudotyp
activ
serum
dilut
data
shown
sampl
test
dilut
valu
set
cutoff
preincub
serum
sampl
serial
dilut
preincub
viru
inocul
onto
vero
cell
infecti
foci
count
figur
show
dynam
cumul
percentag
pseudotyp
infect
use
serum
sampl
collect
three
subject
sampl
consid
nabposit
infect
inhibit
greater
compar
serumneg
control
nab
detect
serum
sampl
collect
earlier
stage
ie
serum
sampl
collect
march
serum
sampl
collect
march
infect
pseudotyp
presenc
dilut
serum
sampl
rang
serum
neg
control
data
shown
contrast
serum
sampl
collect
three
subject
later
stage
march
show
reduct
number
foci
fig
result
indic
serum
sampl
contain
nab
nab
titer
defin
reciproc
highest
dilut
inhibit
infect
observ
serum
sampl
collect
march
shown
nab
titer
respect
nab
titer
use
sarscov
convent
neutral
assay
respect
data
shown
result
neutral
assay
use
good
agreement
neutral
assay
use
sarscov
nab
titer
obtain
vsvbase
neutral
assay
twoto
fourfold
higher
obtain
convent
neutral
assay
valid
neutral
assay
addit
neutral
assay
carri
subset
serum
sampl
collect
healthcar
worker
hanoi
french
hospit
titer
nab
determin
use
compar
use
convent
neutral
assay
infecti
sarscov
thirtythre
serum
sampl
shown
posit
either
neutral
assay
shown
figur
signific
posit
correl
correl
coeffici
nab
titer
determin
sarscov
serum
sampl
posit
neutral
assay
neg
convent
neutral
assay
tabl
possibl
falseposit
result
three
sampl
assay
exclud
howev
seem
like
three
sera
extrem
low
titer
nab
sarscov
sera
collect
subject
day
later
high
nab
titer
data
shown
furthermor
among
three
serum
sampl
one
posit
rnpbase
elisa
od
valu
dilut
data
shown
indic
serum
contain
antibodi
sarscov
taken
togeth
result
suggest
neutral
assay
sensit
convent
neutral
assay
use
sarscov
assumpt
support
observ
nab
titer
measur
use
higher
measur
convent
neutral
assay
fig
neutral
data
obtain
serum
sampl
neutral
assay
use
sarscov
refer
method
show
sensit
specif
neutral
assay
respect
tabl
neutral
assay
gold
standard
test
antibodi
sarscov
specif
sensit
compar
neutral
data
indic
good
correl
convent
neutral
assay
use
sarscov
neutral
assay
reliabl
serolog
test
sarscov
infect
pseudotypebas
neutral
assay
requir
handl
infecti
sarscov
safeti
concern
led
sever
laboratori
util
replicationincompet
retrovirusbas
sarscov
pseudotyp
assess
nab
sarscov
nie
et
al
temperton
et
al
retroviru
pseudotypebas
neutral
assay
shown
sensit
specif
convent
neutral
assay
nie
et
al
temperton
et
al
howev
time
requir
determin
viru
infect
j
med
virol
doi
correl
neutral
antibodi
titer
measur
use
pseudotyp
measur
use
sarscov
correl
coeffici
nab
titer
log
valu
sarscov
neutral
assay
plot
yaxi
scale
wherea
vsvbase
assay
plot
xaxi
scale
retroviru
system
hr
similar
time
requir
sarscov
replic
level
result
plaqueform
cytopath
effect
infect
cell
contrast
use
vsvdg
system
advantag
rapid
detect
pseudotyp
infect
ogino
et
al
recent
report
upon
infect
vero
cell
pseudotyp
infect
cell
detect
hr
postinfect
due
rapid
express
gfp
vsvdg
system
furthermor
quantit
analysi
infect
perform
easili
count
number
gfpposit
cell
use
imagej
softwar
http
rsbinfonihgovij
thu
novel
nab
assay
system
allow
measur
sarscovspecif
nab
within
day
present
studi
establish
rapid
safe
sarscovneutr
assay
use
pseudotyp
result
obtain
use
system
show
good
correl
obtain
use
convent
neutral
assay
sarscov
furthermor
novel
nab
assay
appear
sensit
low
antibodi
titer
serum
sampl
thu
provid
use
tool
detect
nab
sarscov
